Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.84 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.84 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.84 |
| ▸ | XDH | P47989 | 2/20 | 0.84 |
| ▸ | IPMK | Q8NFU5 | 2/20 | 0.84 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.84 |
| ▸ | CA12 | O43570 | 1/20 | 0.84 |
| ▸ | CA2 | P00918 | 1/20 | 0.84 |
| ▸ | CA4 | P22748 | 1/20 | 0.84 |
| ▸ | PPARG | P37231 | 1/20 | 0.84 |
| ▸ | CA7 | P43166 | 1/20 | 0.84 |
| ▸ | DPP4 | P27487 | 1/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.82 |
| ▸ | LMNA | P02545 | 3/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.82 |
| ▸ | MAPT | P10636 | 3/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.82 |
| ▸ | APP | P05067 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rhamnazin SCHEMBL29724889 | 1.00 | MEN1 (0.84) | MEN1KMT2ACYP1A1CYP1A2CYP1B1 | |
| SCHEMBL1250547 | 0.93 | XDH (0.86) | MEN1KMT2ACYP1A1CYP1A2CYP1B1 | |
| Isorhamnetin SCHEMBL29390102 | 0.91 | MEN1 (1.00) | MEN1KMT2ACYP1A1CYP1A2CYP1B1 | |
| Isorhamnetin SCHEMBL19235 | 0.91 | MEN1 (1.00) | MEN1KMT2ACYP1A1CYP1A2CYP1B1 | |
| Isorhamnetin SCHEMBL29377152 | 0.91 | MEN1 (1.00) | MEN1KMT2ACYP1A1CYP1A2CYP1B1 | |
| Isorhamnetin SCHEMBL30385934 | 0.91 | MEN1 (1.00) | MEN1KMT2ACYP1A1CYP1A2CYP1B1 | |
| Ombuine SCHEMBL1252211 | 0.90 | XDH (1.00) | MEN1KMT2ACYP1A1CYP1A2CYP1B1 | |
| Ombuine SCHEMBL31516400 | 0.90 | XDH (1.00) | MEN1KMT2ACYP1A1CYP1A2CYP1B1 | |
| Ombuine SCHEMBL29475881 | 0.90 | XDH (1.00) | MEN1KMT2ACYP1A1CYP1A2CYP1B1 | |
| Rhamnetin SCHEMBL555118 | 0.90 | MEN1 (1.00) | MEN1KMT2ACYP1A1CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1378 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3346842-B1 | STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME | NOVONESIS PLANT BIOSOLUTIONS AS (DK) | 2026-03-25 | — | — | EP | claimed |
| US-12514929-B2 | Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-06 | — | — | US | claimed |
| WO-2025235852-A1 | FLAVONOID COMPOSITIONS AND METHODS OF USE | SYNGENTA CROP PROTECTION AG (CH) | 2025-11-13 | — | — | WO | claimed |
| US-12458049-B2 | Steviol glycoside solubility enhancers | CARGILL, INCORPORATED (US) | 2025-11-04 | — | — | US | claimed |
| WO-2025038482-A2 | USE OF FISETIN FOR REDUCING THE INCIDENCE OF ATRIAL FIBRILLATION | RHODE ISLAND HOSPITAL (US) | 2025-02-20 | — | — | WO | claimed |
| CN-119326748-A | Application of traditional Chinese medicine single rhamnozine in preparation of leukemia treatment medicine | 东莞市人民医院 | 2025-01-21 | — | — | CN | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20240293600-A1 | COMPOSITIONS, METHODS, AND DEVICES FOR SUSTAINED RELEASE OF AN AGENT | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2024-09-05 | — | — | US | claimed |
| US-20240188613-A1 | SWEETENER COMPOSITIONS COMPRISING MOGROSIDES AND USES THEREOF | FIRMENICH INCORPORATED | 2024-06-13 | — | — | US | claimed |
| CN-118078848-A | Application of rhamnozine-3-O-B-D-glucoside and anti-tumor metastasis medicine | 江西中医药大学 | 2024-05-28 | — | — | CN | claimed |
| US-20070251024-A1 | COMPOSITION FOR DYEING KERATIN FIBERS AND A METHOD OF DYEING HAIR USING SAME | ADVANCED COSMETIC TECHNOLOGIES, LLC | 2007-11-01 | — | — | US | claimed |
| US-20040162247-A1 | Therapeutic agent or osteoporosis comprising an active ingredient of quercetin derivatives | KIM CHUNG-SOOK (KR) | 2004-08-19 | — | — | US | claimed |
| EP-1309326-A1 | A THERAPEUTIC AGENT OF OSTEOPOROSIS COMPRISING AN ACTIVE INGREDIENT OF QUERCETIN DERIVATIVES | Korea Institute of Oriental Medicine (KR) | 2003-05-14 | — | — | EP | claimed |
| US-20020165169-A1 | Therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2002-11-07 | — | — | US | claimed |
| WO-2002017909-A1 | A THERAPEUTIC AGENT OF OSTEOPOROSIS COMPRISING AN ACTIVE INGREDIENT OF QUERCETIN DERIVATIVES | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2002-03-07 | — | — | WO | claimed |
| EP-0290442-A4 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS. | CHEMEX PHARMACEUTICALS INC (US) | 1990-07-03 | — | — | EP | claimed |
| EP-0290442-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-11-17 | — | — | EP | claimed |
| US-4774229-A | ANTITUMOR AGENTS, SKIN DISORDERS, CANCER TREATMENT | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-09-27 | — | — | US | claimed |
| WO-1988003805-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | claimed |
| WO-1987006833-A1 | MODIFICATION OF PLANT EXTRACTS FROM ZYGOPHYLLACEAE | CHEMEX PHARMACEUTICALS, INC. (US) | 1987-11-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458049-B2 | Steviol glycoside solubility enhancers | SI, TAS2R7, TAS2R31 | MEN1 679/4885KMT2A 1638/4885CYP1A1 1771/4885 |
| US-20040162247-A1 | Therapeutic agent or osteoporosis comprising an active ingredient of quercetin derivatives | NFATC1, MKI67, SOST | MEN1 2365/4885KMT2A 1928/4885CYP1A1 2740/4885 |
| US-20020165169-A1 | Therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives | NFATC1, MKI67, SOST | MEN1 2560/4885KMT2A 1994/4885CYP1A1 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.